121507-34-4

Basic information

• Product Name: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)
• Synonyms: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI);5-(propan-2-yloxy)-1H-pyrazol-3-aMine;1H-Pyrazol-3-aMine, 5-(1-Methylethoxy)-
• CAS NO: 121507-34-4
• Molecular Formula: C₆H₁₁N₃O
• Molecular Weight: 141.17104
• Product Categories: VARIOUSAMINE
• Mol File: 121507-34-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)(121507-34-4)
• EPA Substance Registry System: 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI)(121507-34-4)

Safety Data

• Hazardous Substances Data: 121507-34-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI) is used as a key intermediate in the synthesis of various biologically active compounds. It plays a crucial role in the development of potent inhibitors of Trk kinases, which are important targets for the treatment of various cancers and neurological disorders.
Used in Chemical Synthesis:
In the chemical industry, 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI) serves as a versatile building block for the creation of a wide range of chemical compounds. Its unique structure allows for further functionalization and modification, making it a valuable asset in the synthesis of new molecules with potential applications in various fields.
Used in Research and Development:
1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI) is also utilized in research and development for the evaluation of its biological properties and potential therapeutic effects. 1H-Pyrazol-3-amine,5-(1-methylethoxy)-(9CI) can be used to study the mechanisms of action of Trk kinase inhibitors and to develop new strategies for the treatment of cancer and other diseases.

Upstream product

• 140-87-4 Cyanoacetohydrazide 
• 67-63-0 isopropyl alcohol 
• 53666-79-8 5-amino-2H-pyrazol-3-ol 

Downstream Products

• 1269515-15-2 2,6-difluoro-N-(2-isopropoxypyrazolo[1,5-a]pyrimidin-6-yl)-3-(propylsulfonamido)benzamide 
• 1079274-94-4 (S)-N-(1-(5-fluoropyrimidin-2-yl)ethyl)-3-(5-isopropoxy-1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine 
• 1192233-23-0 N-(5-isopropoxy-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-yl)-3-(pyridin-2-ylsulfonyl)benzamide 
• 1192232-58-8 N-(3-isopropoxy-1H-pyrazol-5-yl)-3-(pyridin-2-ylsulfonyl)benzamide 
• 868596-01-4 N-(5-fluoro-2-nitrophenyl)-5-isopropoxy-1H-pyrazol-3-amine 

Relevant articles and documents

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment

LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT

[Problem] To provide compounds useful as preventives or remedies for circular system disorders, nervous system disorders, metabolic disorders, reproduction system disorders, digestive system disorders, neoplasm, infectious diseases, etc., or as herbicides. [Means for Solution] A long-chain fatty acyl elongase inhibitor comprising, as the active ingredient thereof, a compound or a pharmaceutically-active salt thereof of a formula (I): [wherein W represents a hydrogen atom, a C1-6 alkyl, etc.; X represents an aryl, a heteroaryl, etc.; n indicates 0 or 1; Z represents a hydrogen atom, a C1-6 alkyl, etc.; A1, A2, A3 and A4 each independently represent CH or N].

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases

The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These compounds provide a treatment for myeloproliferative disorders and cancer.

5-AMINOPYRAZOL-3-YL-3H-IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.

PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES

Compounds of formula (I): and their use in the inhibition of Trk activity are described.